• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Retaine now available in multi-dose, preservative-free bottle

Article

OcuSOFT’s Retaine HPMC lubricant eye drops will now be available in a patented multi-dose, preservative-free delivery system.

 

Rosenberg, TX-OcuSOFT’s Retaine HPMC lubricant eye drops will now be available in a patented multi-dose, preservative-free delivery system.

The new delivery system for the eye drops-a preservative-free hyporomellose ophthalmic solution (0.3%) that provides immediate relief to soothe dry, irritated eyes by resembling natural tears-utilizes a proprietary airless pump system that prevents harmful bacteria from entering the bottle and contaminating the solution.

“(The eye drops) remains the gold standard for patients with more demanding dry eye conditions,” said Stacy Foster, executive vice president of OcuSOFT. “However, for patients with less severe conditions, and where budget concerns exist, (the eye drops) with its multi-dose, preservative-free pump dispenser is ideal.

“A measured release 10 ml bottle contains 300 drops offer the benefit of preservative-free dosing without unit-of-use container cost,” Foster added.

The new system was also presented during SECO last week, and will again be shown during Vision Expo East next week in New York City.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Related Videos
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.